The Lancet Gastroenterology & Hepatology
LightNews LightNews
banner
lancetgastrohep.bsky.social
The Lancet Gastroenterology & Hepatology
@lancetgastrohep.bsky.social
1.2K followers 78 following 230 posts
The Lancet Gastroenterology & Hepatology is the world-leading #gastroenterology and #hepatology research journal. IF=39.1.

🌐 thelancet.com/journals/langas/home
Posts Replies Media Videos
Pinned
lancetgastrohep.bsky.social
The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · Jul 1
We are the world-leading journal dedicated to #gastroenterology and #hepatology research and review, ranking:  

#1 for Scopus CiteScore (64·3)  

#3 for Journal Impact Factor (39·1)  

Explore our high impact and global reach: hubs.li/Q04k--0J0  

#GastroSky #LiverSky
About The Lancet Gastroenterology & Hepatology
hubs.li
lancetgastrohep.bsky.social
New Research - Genetic variants and the risk of renal impairment in decompensated cirrhosis: a multi-ancestry genome-wide association study

www.thelancet.com/journals/lan...

#LiverSky #MedSky
Genetic variants and the risk of renal impairment in decompensated cirrhosis: a multi-ancestry genome-wide association study
SUSD1 is a risk locus for renal impairment in decompensated cirrhosis, with genetic effects that appear context-dependent across cirrhosis stages and the general population. Our findings implicate the...
www.thelancet.com
September 21, 2026 at 10:26 AM
lancetgastrohep.bsky.social
🆕Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial

www.thelancet.com/journals/lan...

#GastroSky #IBDSky #MedSky
Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial
Early top-down anti-TNF treatment from diagnosis was associated with improved long-term outcomes at 5 years compared with step-up treatment and is suggestive of a disease-modifying effect in Crohn's disease.
www.thelancet.com
September 11, 2026 at 9:12 AM
lancetgastrohep.bsky.social
🆕Germline multigene panel testing for colorectal cancer: a systematic review and meta-analysis

www.thelancet.com/journals/lan...

#GastroSky #MedSky #OncSky
September 4, 2026 at 1:28 PM
lancetgastrohep.bsky.social
The Oct 2026 issue of @LancetGastroHep is out today! www.thelancet.com/gastrohep

Content includes: #colorectalcancer, #MASLD, #viralhepatitis, #DGBI, #LynchSyndrome, bowel #endometriosis + more!

#GastroSky #LiverSky #MedSky #OncSky
September 3, 2026 at 8:09 AM
Reposted by The Lancet Gastroenterology & Hepatology
lancetrh-wpac.bsky.social
Our new issue is live!🙌

Check out papers about new point-of-care diagnosis triage for #COPD, climate hazard and #MentalHealth hospitalisations, #UlcerativeColitis sub-phenotyping, and long-term #cancer prevalence projection in #Australia... & more!

🔗 www.thelancet.com/journals/lan...
September 2, 2026 at 2:55 AM
Reposted by The Lancet Gastroenterology & Hepatology
lancetimaging.bsky.social
📢 We’ve published our first issue!

Read and download our inaugural issue here ➡️ www.thelancet.com/issue/S3117-...

Thank you to our authors and reviewers for their valuable contributions ✨

As a gold open access journal, our content is free to read by everyone, always. #OA

#MedSky #RadSky
Image ALT text: Representative images of individuals with different NMN BBB scores. The left column shows contrast enhanced MRI brain scans and the right column shows the fusion of the MRI scans and PET scans of these same individuals. The top row corresponds to an individual with a NMN BBB score of 2 as minor parts of PET-positive volume show contrast enhancement on MRI. The bottom row corresponds to an individual with a NMN BBB score of 5 as the PET positive volume shows complete contrast enhancement on MRI. Copyright: The authors, Nathalie Albert and colleagues. Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
August 27, 2026 at 11:15 AM
lancetgastrohep.bsky.social
New research - ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial

www.thelancet.com/journals/lan...

#MASH #MASLD #LiverSky #MedSky #GastroSky
ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial
Statistically significant reductions in liver fat with ALG-055009 and no relevant safety issues suggest that ALG-055009 could offer a promising treatment approach for patients with MASH. Results suppo...
www.thelancet.com
August 27, 2026 at 7:54 AM
lancetgastrohep.bsky.social
New research - On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial

www.thelancet.com/journals/lan...

#GastroSky #LiverSky #OncSky #MedSky
On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 tri...
On-demand TACE plus atezolizumab and bevacizumab significantly improved TACE-PFS versus on-demand TACE alone. Overall survival follow-up is ongoing.
www.thelancet.com
August 26, 2026 at 8:23 AM
Reposted by The Lancet Gastroenterology & Hepatology
thelancetendo.bsky.social
Early booking for the #LancetSummit is open until Sep 4, 2026. Register now to save on fees and join leading experts to discuss the latest advances in #diabetes research, prevention, and care.
👉 View the preliminary programme and register at
thelancetsummit.com/diabetes-pre... .
August 23, 2026 at 3:30 PM
Reposted by The Lancet Gastroenterology & Hepatology
thelancetoncol.bsky.social
🔴Online now: ChemoRT vs short-course RT for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of a randomised, phase 2/3 trial

📉Article: thelancet.com/journals/lan...
&

✏️ Comment: thelancet.com/journals/lan...
August 24, 2026 at 8:33 AM
Reposted by The Lancet Gastroenterology & Hepatology
eclinicalmed.bsky.social
📢NEW: August issue now online featuring #HepB, #MS, #BreastCancer, #Psoriasis, #COVID, #Psychosis, #MacularOedema, and more, with our editorial on #heatwaves and health system resilience

…all available #free, #OpenAccess❗️

Read here: www.thelancet.com/issue/S2589-...

Attribution: Getty
#MedSky
August 24, 2026 at 11:35 AM
Reposted by The Lancet Gastroenterology & Hepatology
thelancetoncol.bsky.social
🆕Our Sept issue is now live!

📊Articles: #hepatocellularcarcinoma #NSCLC #rectalcancer #breastcancer #prostatecancer

📉Featuring trials: EMERALD-3, HARMONi, ALINA, STAR-TREC, & GETUG AFU 18

🎨Cover: breast cancer, TILs, and AI

🖱️Read here: www.thelancet.com/issue/S1470-...
August 25, 2026 at 10:06 AM
lancetgastrohep.bsky.social
New Review - The trajectory of inflammatory bowel disease in east and southeast Asia: transitioning from acceleration in incidence to compounding prevalence

www.thelancet.com/journals/lan...

#GastroSky #IBDSky #MedSky
The trajectory of inflammatory bowel disease in east and southeast Asia: transitioning from acceleration in incidence to compounding prevalence
The epidemiology of inflammatory bowel disease (IBD) progresses through four stages: emergence (stage 1), acceleration in incidence (stage 2), compounding prevalence (stage 3), and prevalence equilibr...
www.thelancet.com
August 13, 2026 at 7:41 AM
lancetgastrohep.bsky.social
New research - A blood-based test for detection of advanced adenomas and colorectal cancer (DENEB): a multicentre diagnostic accuracy study

www.thelancet.com/journals/lan...

#GastroSky #OncSky #Colorectalcancer #MedSky
www.thelancet.com
August 11, 2026 at 11:54 AM
lancetgastrohep.bsky.social
🎉Our 10th anniversary issue is out now, featuring a collection of Comments looking back over the past decade in key areas of gastroenterology & hepatology + our usual range of content covering topics incl #IBD, #LynchSyndrome, #MASH + more!

www.thelancet.com/gastrohep

#GastroSky #MedSky #LiverSky
August 6, 2026 at 6:30 AM
Reposted by The Lancet Gastroenterology & Hepatology
thelancet.com
Three in four eating disorder patients are not referred for specialist care, UK study suggests body weight may be a factor.

Find out more in @lancetprimarycare.bsky.social: spkl.io/633267zsbC
Research in context panel for a paper published in The Lancet Primary Care, entitled \"Weight status and pathways to eating disorder referral from primary care in England and Northern Ireland: a cross-sectional analysis of routine care data\". Copyright: 2026 The Author(s). Published by Elsevier Ltd. CC BY-NC-ND 4.0.
August 5, 2026 at 3:07 PM
lancetgastrohep.bsky.social
🆕Review on barrier restoration as a therapeutic strategy for disorders of gut–brain interaction.

Check it out here ➡️ www.thelancet.com/journals/lan...

#GastroSky #MedSky
July 30, 2026 at 8:21 AM
lancetgastrohep.bsky.social
Its World Hepatitis Day.

Check out:

🆕 A Comment discussing the 2026 WHO global hepatitis report. www.thelancet.com/journals/lan...

🆕A Comment discussing the launch of the Africa CDC toolkit for hepatitis B. www.thelancet.com/journals/lan...

#worldhepatitisday #nohep #LiverSky #HepSky
July 28, 2026 at 8:54 AM
Reposted by The Lancet Gastroenterology & Hepatology
thelancet.com
🔔 Discover The Lancet Surgery & Anaesthesiology, a new journal with a sharp clinical focus, dedicated to advancing science across the full extent of #surgery, #anaesthesiology, and #perioperative specialties, across the age spectrum, and across the globe: spkl.io/633237JQbc
Illustration of a female in green scrubs, cap, and blue surgical mask, surrounded by four smaller illustrations showing surgical instruments and operating room scenes. Copyright: Grace Russell.
July 23, 2026 at 8:16 AM
Reposted by The Lancet Gastroenterology & Hepatology
thelancet.com
Irritable bowel syndrome (IBS) affects 5–10% of people worldwide.

A new Review discusses the current understanding of the pathophysiology of IBS in terms of peripheral, central, and integrated mechanisms.

Read in @lancetgastrohep.bsky.social: tinyurl.com/5cankju9
Figure showing peripheral mechanisms contributing to IBS. This figure was created using BioRender.com. IBS=irritable bowel syndrome. Copyright: 2026 Elsevier Ltd. All rights are reserved.
July 23, 2026 at 7:34 AM
lancetgastrohep.bsky.social
🆕The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, placebo-controlled, phase 2 trial

www.thelancet.com/journals/lan...

#LiverSky #MedSky
The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multic...
In this prespecified 12-week primary analysis, DD01 produced rapid reductions in liver fat compared with placebo, supporting further evaluation in long-term studies.
www.thelancet.com
July 22, 2026 at 7:11 AM
lancetgastrohep.bsky.social
🆕Artificial intelligence-assisted detection and optical differentiation of colorectal lesions in Lynch syndrome surveillance (CADLY2): a multicentre, open-label, randomised controlled superiority trial

www.thelancet.com/journals/lan...

#GastroSky #OncSky #MedSky #AI
Artificial intelligence-assisted detection and optical differentiation of colorectal lesions in Lynch syndrome surveillance (CADLY2): a multicentre, open-label, randomised controlled superiority trial
CADe-assisted colonoscopy did not show the absolute improvement in adenoma detection rate that was assumed in the prespecified sample-size calculation. CADx did not clearly improve lesion differentiat...
www.thelancet.com
July 17, 2026 at 5:22 AM
lancetgastrohep.bsky.social
🆕Results from RELIEVE UCCD - efficacy and safety of duvakitug in patients with Crohn's disease or ulcerative colitis

UC - www.thelancet.com/journals/lan...

CD - www.thelancet.com/journals/lan...

#GastroSky #MedSky #IBDSky
Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial
Duvakitug showed significant evidence for clinical remission versus placebo, with no safety concerns identified, in patients with moderately to severely active ulcerative colitis.
www.thelancet.com
July 17, 2026 at 5:20 AM
lancetgastrohep.bsky.social
New - Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2 randomised controlled trial

www.thelancet.com/journals/lan...

#LiverSky #MedSky
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-b...
In participants with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis, the combination of zalfermin 30 mg plus semaglutide 2·4 mg did not significantly increase the...
www.thelancet.com
July 16, 2026 at 3:28 PM
Reposted by The Lancet Gastroenterology & Hepatology
thelancetendo.bsky.social
Read our August Issue, featuring advances in lipid-lowering therapies, phaeochromocytomas and paragangliomas, sleeve gastrectomy, type 2 diabetes, postpartum depression, diabetic foot ulcers, CGM, obesity medications & much more tinyurl.com/mwfu4c6m

#MedSky #EndoSky #CardioSky #GastroSky #PsychSky
July 14, 2026 at 10:33 PM